

**Dose Response and Concentration  
Response Analysis of Drug Effects**

**Juan J. L. Lertora. M.D., Ph.D.  
NIH Clinical Center  
January 27, 2011**

## **DOSE-EFFECT RELATIONSHIP**

**The intensity and duration of a drug's effects are a function of the drug dose and drug concentration at the effect site**

**(The contribution of Frank M. Balis, M.D. is gratefully acknowledged)**

## Monitoring Dose-Effect

- **Level**
  - Molecular (e.g, enzyme inhibition)
  - Cellular (*in vitro* tissue culture, blood cells)
  - Tissue or organ (*in vitro* or *in vivo*)
  - Organism
- **Endpoint used to measure effect may be different at each level**
- **Overall effect = sum of multiple drug effects and physiological response to drug effects**

## **Endpoints to Monitor Drug Effect**

### **Farnesyltransferase Inhibitors for Cancer**

<b>LEVEL</b>	<b>ENDPOINT</b>
<b>Molecular</b>	<b>Farnesyltransferase inhibition</b>
<b>Cellular</b>	<b>Proliferation rate, apoptosis</b>
<b>Tumor</b>	<b>Response (change in tumor size)</b>
<b>Organism</b>	<b>Survival, quality of life</b>

## Dose-Effect Endpoints


### Graded

- Continuous scale ( $\uparrow$ dose  $\rightarrow$   $\uparrow$ effect)
- Measured in a single biologic unit
- Relates dose to intensity of effect

### Quantal


- All-or-none pharmacologic effect
- Population studies
- Relates dose to frequency of effect

## Erythropoietin and Anemia



Eschbach et al. NEJM 316:73-8, 1987

## Drug-Receptor Interactions



$$\text{Effect} = \frac{\text{Maximal effect} \cdot [\text{Drug}]}{K_D + [\text{Drug}]}$$
$$(K_D = k_2/k_1)$$

## Dose-Effect Relationship


$$\text{Effect} = \frac{\text{Maximal effect} \cdot [\text{Drug}]}{K_D + [\text{Drug}]}$$

$$\text{Effect} = \text{Maximal effect} \frac{[\text{Drug}]}{K_D + [\text{Drug}]}$$


$$\text{Effect} = \text{Maximal effect} \quad \text{if } [\text{Drug}] \gg K_D$$




## Graded Dose-Effect Curve



## Log Dose-Effect Curve




## Lidocaine Graded Dose-Effect




Ferrante et al. Anesth Analg 82:91-7, 1996

## Theophylline Dose-Effect




Rabe et al. Eur Respir J 8:637-42, 1995

## Theophylline Pharmacodynamics



Mitenko & Ogilvie NEJM 289:600-3, 1973

## Metformin Dose-Response




Garber et al. Am J Med 102:491-7, 1997

## **Dose-Effect Parameters**

**POTENCY:** The sensitivity of an organ or tissue to the drug


**EFFICACY:** The maximum effect

## Comparing Dose-Effect Curves






# Thiopurine Cytotoxicity




Adamson et al. Leukemia Res 18:805-10, 1994

# Thiopurine Metabolic Activation




## Oral Mercaptopurine




Balis et al. Blood 92:3569-77, 1998

## Receptor-Mediated Effects




## Drug Interactions




## **Graded Dose-Effect Analysis**

- **Identify the therapeutic dose/concentration**
- **Define site of drug action (receptor)**
- **Classify effect produced by drug-receptor interaction (agonist, antagonist)**
- **Compare the relative potency and efficacy of drugs that produce the same effect**
- **Assess mechanism of drug interactions**

## Quantal Dose-Effect Distribution



## Cumulative Dose-Effect Curve






## Cumulative Dose-Effect Study

<b>Dose Level</b>	<b>No. of Subjects</b>	<b>No. Responding</b>	<b>% Response</b>
1	10	0	0
2	10	1	10
3	10	3	30
4	10	5	50
5	10	7	70
6	10	8	80
7	10	9	90
8	10	10	100

## Therapeutic and Toxic Effects



Indices


## Therapeutic Indices

$$\text{Therapeutic Ratio} = \frac{\text{TD}_{50}}{\text{ED}_{50}} = 2.5$$


$$\text{Certain Safety Factor} = \frac{\text{TD}_1}{\text{ED}_{99}} = 1.3$$

$$\text{Standard Safety Margin} = \frac{\text{TD}_1 - \text{ED}_{99}}{\text{ED}_{99}} \times 100 = 31\%$$

## Digoxin Therapeutic Index




## Doxorubicin Cardiotoxicity



von Hoff et al. Ann Intern Med 91:710-7, 1979

## Lidocaine Quantal Dose-Effect




Ferrante et al. Anesth Analg 82:91-7, 1996

## Antihypertensive Dose-Effect

Drug	Dose Range [mg]		Lowest Effective Dose [mg]
	Early Studies	Present Dose	
Propranolol	160-5000	160-320	80
Atenolol	100-2000	50-100	25
Hydrochlorthiazide	50-400	25-50	12.5
Captopril	75-1000	50-150	37.5
Methyldopa	500-6000	500-3000	750


Johnston Pharmacol Ther 55:53-93, 1992

## Antihypertensive Drugs







## Relating Dose to Effect *In Vivo*



## Effect Compartment (PK/PD Model)



## Concentration and Effect vs. Time



## Pharmacodynamic Models

- Fixed effect model

- Linear model

$$Effect = E_0 + S \cdot [Drug]$$

- Log-linear model

$$Effect = I + S \cdot \text{Log}([Drug])$$


- $E_{\max}$  model

$$Effect = \frac{E_{\max} \cdot [Drug]^H}{EC_{50}^H + [Drug]^H}$$


- Sigmoid  $E_{\max}$  model

## Sigmoid $E_{\max}$ PD Model

Effect (%)



Effect (%)




[Drug]

# Hysteresis and Proteresis Loops


Intensity of  
Drug Effect

Hysteresis Loop  
(Counterclockwise)



Intensity of  
Drug Effect

Proteresis Loop  
(Clockwise)



Plasma Drug Concentration

## **Role of Dose-Effect Studies**

- **Drug development**
  - Site of action
  - Selection of dose and schedule
  - Potency, efficacy and safety
  - Drug interactions
- **Patient management**
  - Therapeutic drug monitoring
  - Risk-benefit (therapeutic indices)